Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Joel Marrs

Concepts (168)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antihypertensive Agents
5
2021
442
1.870
Why?
Hypertension
7
2021
1140
1.760
Why?
Aspirin
3
2015
285
1.460
Why?
Platelet Aggregation Inhibitors
3
2015
343
1.400
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
6
2020
394
1.170
Why?
Diabetes Mellitus, Type 2
7
2017
1866
1.160
Why?
Atrial Fibrillation
2
2019
330
1.070
Why?
Anticoagulants
2
2019
509
1.040
Why?
Stroke
4
2019
873
0.980
Why?
Thiophenes
2
2015
107
0.930
Why?
Allylamine
2
2012
8
0.910
Why?
Hypolipidemic Agents
3
2011
94
0.880
Why?
Internship, Nonmedical
2
2010
18
0.770
Why?
Medication Reconciliation
1
2018
27
0.740
Why?
Kidney Failure, Chronic
2
2011
418
0.650
Why?
Dyslipidemias
3
2019
161
0.650
Why?
Cardiovascular Diseases
6
2019
1633
0.630
Why?
Cholesterol, LDL
5
2019
317
0.610
Why?
Pharmaceutical Services
2
2020
76
0.610
Why?
Heart Failure, Diastolic
1
2015
25
0.600
Why?
Pharmacists
5
2020
234
0.600
Why?
Drug-Eluting Stents
1
2015
78
0.590
Why?
Thromboembolism
1
2015
98
0.580
Why?
Ticlopidine
1
2015
66
0.580
Why?
Medically Underserved Area
1
2015
100
0.570
Why?
Hypoglycemic Agents
2
2012
932
0.560
Why?
Practice Guidelines as Topic
5
2019
1541
0.550
Why?
Education, Pharmacy
3
2017
152
0.520
Why?
Patient Discharge
2
2018
675
0.520
Why?
Venous Thromboembolism
1
2015
177
0.510
Why?
Piperazines
1
2015
308
0.500
Why?
Thrombosis
1
2015
244
0.500
Why?
Urban Population
1
2015
415
0.500
Why?
Blood Pressure
3
2016
1703
0.490
Why?
Guideline Adherence
1
2016
522
0.490
Why?
Glucosides
1
2012
31
0.490
Why?
Anticholesteremic Agents
2
2012
141
0.450
Why?
Spironolactone
1
2010
38
0.440
Why?
Mineralocorticoid Receptor Antagonists
1
2010
57
0.430
Why?
Preceptorship
1
2010
55
0.410
Why?
Administration, Oral
3
2019
796
0.400
Why?
Humans
37
2021
109171
0.400
Why?
Professional Role
3
2020
156
0.380
Why?
Medication Therapy Management
2
2020
67
0.380
Why?
Students, Pharmacy
1
2010
115
0.380
Why?
Benzodiazepines
1
2008
110
0.360
Why?
Drug Therapy, Combination
4
2016
1021
0.350
Why?
Renal Dialysis
1
2010
304
0.350
Why?
Angiotensin Receptor Antagonists
2
2021
68
0.340
Why?
Angiotensin-Converting Enzyme Inhibitors
3
2021
221
0.340
Why?
Dipeptidyl-Peptidase IV Inhibitors
1
2007
41
0.340
Why?
Sleep Initiation and Maintenance Disorders
1
2008
114
0.340
Why?
Hypnotics and Sedatives
1
2008
159
0.340
Why?
Hospitalization
2
2015
1580
0.330
Why?
Insurance Coverage
1
2008
204
0.330
Why?
Certification
3
2013
111
0.320
Why?
Family Practice
2
2010
471
0.320
Why?
Heart Failure
1
2018
1806
0.310
Why?
Schools, Pharmacy
2
2017
58
0.300
Why?
Faculty
2
2017
110
0.290
Why?
Poverty
1
2008
436
0.280
Why?
Ambulatory Care
1
2007
452
0.260
Why?
Specialization
3
2013
120
0.260
Why?
Colesevelam Hydrochloride
2
2012
8
0.230
Why?
Aged
9
2020
19759
0.230
Why?
Pharmacy Service, Hospital
2
2013
84
0.230
Why?
Cell Phone
1
2021
66
0.220
Why?
Retrospective Studies
6
2021
10640
0.220
Why?
Cardiovascular Agents
1
2021
128
0.210
Why?
Diabetes Mellitus
2
2020
879
0.210
Why?
Brain Ischemia
2
2013
265
0.210
Why?
Secondary Prevention
3
2016
243
0.210
Why?
Text Messaging
1
2021
128
0.200
Why?
Female
12
2021
61606
0.200
Why?
Blood Glucose
3
2012
1779
0.180
Why?
Heart Valve Diseases
1
2019
180
0.180
Why?
Age Factors
2
2016
3307
0.180
Why?
Middle Aged
9
2020
28539
0.170
Why?
4-Hydroxycoumarins
1
2016
7
0.170
Why?
Dissociative Disorders
1
2016
23
0.170
Why?
Vitamin K
1
2016
44
0.170
Why?
Cholesterol
3
2019
382
0.160
Why?
Community Participation
1
2017
129
0.160
Why?
Risk Factors
5
2019
8786
0.160
Why?
Clinical Trials as Topic
2
2012
992
0.160
Why?
Patient Transfer
1
2018
150
0.160
Why?
Male
10
2020
60174
0.160
Why?
Aged, 80 and over
4
2015
6709
0.150
Why?
Primary Prevention
2
2014
216
0.150
Why?
Suicide, Attempted
1
2016
243
0.140
Why?
Guidelines as Topic
1
2016
276
0.140
Why?
Blood Coagulation Disorders
1
2016
212
0.140
Why?
Diuretics
2
2011
82
0.140
Why?
Adult
7
2021
31455
0.140
Why?
Treatment Outcome
2
2019
8928
0.130
Why?
Societies, Pharmaceutical
2
2017
26
0.130
Why?
Atherosclerosis
1
2015
274
0.130
Why?
Medication Adherence
2
2021
512
0.120
Why?
Follow-Up Studies
3
2016
4830
0.120
Why?
Acute Disease
1
2015
993
0.120
Why?
Benzhydryl Compounds
1
2012
55
0.120
Why?
Cross-Sectional Studies
1
2021
3985
0.120
Why?
Data Collection
1
2014
658
0.120
Why?
Hyperlipidemias
1
2012
145
0.120
Why?
Health Promotion
1
2017
648
0.110
Why?
Universities
1
2013
353
0.110
Why?
Continuity of Patient Care
1
2013
273
0.110
Why?
Sex Factors
1
2016
1949
0.110
Why?
Drug Resistance
1
2010
187
0.100
Why?
Pregnancy
1
2021
5006
0.100
Why?
Interinstitutional Relations
1
2010
67
0.100
Why?
United States
6
2019
11627
0.100
Why?
Drug Monitoring
1
2010
217
0.100
Why?
Myocardial Infarction
1
2016
1111
0.090
Why?
Coronary Artery Disease
1
2015
674
0.090
Why?
Dipeptidyl Peptidase 4
1
2007
8
0.090
Why?
Receptors, GABA-A
1
2008
133
0.090
Why?
Adamantane
1
2007
19
0.090
Why?
Patient-Centered Care
1
2013
451
0.090
Why?
Pyrrolidines
1
2007
40
0.090
Why?
Eicosapentaenoic Acid
1
2006
33
0.080
Why?
Hypertriglyceridemia
1
2006
43
0.080
Why?
Exercise
1
2017
1608
0.080
Why?
Nitriles
1
2007
123
0.080
Why?
Practice Patterns, Physicians'
1
2015
1182
0.080
Why?
Docosahexaenoic Acids
1
2006
65
0.080
Why?
Young Adult
4
2015
10686
0.080
Why?
Insurance, Health
1
2008
256
0.080
Why?
Aging
1
2016
1696
0.080
Why?
Fatty Acids, Omega-3
1
2006
123
0.080
Why?
Hyperglycemia
1
2009
328
0.080
Why?
Risk Assessment
2
2016
3086
0.070
Why?
Triglycerides
1
2006
537
0.070
Why?
Animals
3
2012
34608
0.070
Why?
Adolescent
4
2015
18208
0.070
Why?
Patient Compliance
1
2008
618
0.070
Why?
Enzyme Inhibitors
1
2007
933
0.060
Why?
Sleep
1
2008
669
0.060
Why?
Curriculum
1
2006
753
0.050
Why?
Annual Reports as Topic
1
2017
7
0.050
Why?
Pragmatic Clinical Trials as Topic
1
2017
37
0.050
Why?
Colorado
1
2008
4514
0.040
Why?
Organizational Policy
1
2017
76
0.040
Why?
Advisory Committees
1
2017
196
0.040
Why?
Randomized Controlled Trials as Topic
1
2021
1114
0.040
Why?
Eating
1
2016
330
0.030
Why?
Mechanical Thrombolysis
1
2013
5
0.030
Why?
Clinical Competence
2
2011
881
0.030
Why?
Adrenergic Antagonists
1
2011
8
0.030
Why?
Telephone
1
2013
158
0.030
Why?
Thrombolytic Therapy
1
2013
113
0.030
Why?
Renin
1
2011
37
0.030
Why?
Angiotensin II Type 1 Receptor Blockers
1
2011
43
0.030
Why?
Phytotherapy
1
2011
71
0.030
Why?
Calcium Channel Blockers
1
2011
163
0.030
Why?
Drug Utilization
1
2011
189
0.030
Why?
Cohort Studies
1
2020
4804
0.030
Why?
Patient Care Management
1
2010
61
0.030
Why?
Hospitals, University
1
2010
193
0.030
Why?
Governing Board
1
2009
6
0.030
Why?
Prospective Studies
1
2020
5942
0.020
Why?
Length of Stay
1
2013
1056
0.020
Why?
Databases, Factual
1
2013
1172
0.020
Why?
Patient Readmission
1
2013
597
0.020
Why?
Inpatients
1
2010
310
0.020
Why?
Prevalence
1
2013
2329
0.020
Why?
Drug Combinations
1
2006
281
0.020
Why?
Primary Health Care
1
2015
1452
0.020
Why?
Marrs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2022 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)